Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report)’s share price shot up 5.6% during trading on Tuesday. The stock traded as high as $13.00 and last traded at $12.51. 26,667 shares traded hands during trading, a decline of 96% from the average session volume of 690,737 shares. The stock had previously closed at $11.85.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Bank of America initiated coverage on Iambic Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Research initiated coverage on Iambic Therapeutics in a research report on Tuesday, November 10th. They set a “hold” rating for the company. Jefferies Financial Group began coverage on Iambic Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Iambic Therapeutics in a report on Monday, November 9th. They set an “overweight” rating and a $22.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research report on Saturday, November 7th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Iambic Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $27.25.
Check Out Our Latest Analysis on Iambic Therapeutics
Iambic Therapeutics Trading Up 3.8%
Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($6.23) EPS for the quarter, missing the consensus estimate of ($0.33) by ($5.90). The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $42.50 million. On average, equities research analysts predict that Iambic Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.
Insider Activity at Iambic Therapeutics
In related news, Director Evan Lockwood Rachlin purchased 718,750 shares of the company’s stock in a transaction dated Friday, October 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director directly owned 2,588,248 shares in the company, valued at $41,411,968. The trade was a 38.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.90% of the stock is owned by company insiders.
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
See Also
- Five stocks we like better than Iambic Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
